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Background: Recent studies have suggested that adenosine generated by ecto-5′-nucleotidase (CD73) in the
tumor microenvironment plays a major role in promoting tumor growth by suppressing the immune response and
stimulating angiogenesis via A2A and A2B receptors. However, adenosine has also been reported to inhibit tumor
growth acting via A1 and A3 receptors. Therefore the aim of this study was to clarify the role of host CD73, which
catalyzes the extracellular hydrolysis of AMP to adenosine, on tumor growth and metastasis of B16-F10 melanoma cells.
Methods: CD73 and alkaline phosphatase (AP) activity of B16-F10 melanoma cells were measured by HPLC. Tumor
cells were injected either subcutaneously or intradermally in WT and CD73−/− mice and tumor growth was monitored
by MRI at 9.4 T. Immune cell subpopulations within tumors were assessed by FACS after enzymatic digestion. An
endothelium specific CD73−/− was created using Tie2-Cre+ mice and CD73flox/flox (loxP) mice. Chimeric mice lacking
CD73−/− on hematopoietic cells was generated by bone marrow transplantation. Lung metastatic spread was measured
after intravenous B16-F10 application.
Results: B16-F10 cells showed very little CD73 and negligible AP activity. Neither complete loss of host CD73 nor
specific knockout of CD73 on endothelial cells or hematopoietic cells affected tumor growth after subcutaneous
or intradermal tumor cell application. Only peritumoral edema formation was significantly attenuated in global
CD73−/− mice in the intradermal model. Immune cell composition revealed no differences in the different transgenic
mice models. Also lung metastasis after intravenous B16-F10 injection was not altered in CD73−/− mice.
Conclusions: CD73 expression on host cells, particularly on endothelial and hematopoietic cells, does not modulate
tumor growth and metastatic spread of B16-F10 melanoma cells most likely because of insufficient adenosine
formation by the tumor itself.
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Cancer cells are able to promote their own survival by
changing the tumor microenvironment to their own
favor. One important autocrine and paracrine factor is
the nucleoside adenosine, which accumulates in signifi-
cant quantities in the tumor environment together with
its precursor ATP to finally act on P1 (adenosine) and/* Correspondence: schrader@uni-duesseldorf.de
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unless otherwise stated.or P2 (ATP) receptors [1]. In recent years it became in-
creasingly evident that ATP is released from viable
tumor cells [2] but also from activated immune cells [3]
and subsequently becomes degraded to adenosine by the
ecto-nucleotidases CD39 and CD73 expressed on tumor
and immune cells [4]. Locally formed adenosine is as-
sumed to suppress antitumor immune response, to pro-
mote angiogenesis thereby inhibiting immune-mediated
damage which ultimately promotes tumor progression
[5]. In favor of this hypothesis is the finding that immuno-
genic melanoma cells when subcutaneously inoculated
showed retarded tumor growth and increased survival inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumor growth and vascularization when lung carcin-
oma cells were subcutaneously applied [7]. On the
other hand, adenosine reduced glioblastoma growth
most likely acting via the A1 receptor in microglia [8].
Furthermore, treatment with an A3 agonist significantly
reduced growth of melanoma cells in immune-competent
wildtype (WT) mice [9]. Therefore the outcome of an ade-
nosinergic microenvironment will critically depend on the
expression of adenosine receptor subtypes on the various
immune cell subpopulations and most likely also on the
immunogenicity of tumor cells.
Lately, interest has been shifted towards the sources of
extracellular adenosine, especially the ecto-5′-nucleotidase
(CD73). This ectoenzyme catalyzes dephosphorylation of
extracellular AMP to adenosine, thereby controlling the
decisive step in the extracellular degradation of ATP to ad-
enosine [5]. The role of CD73 expression on tumor cells
has been studied by several groups and its stimulating
influence on tumor growth and metastasis was demon-
strated in vitro and in vivo [10-12]. Recent studies have in-
vestigated the role of CD73 expressed on host cells in
different tumor cell models using CD73−/− mice [13-16],
pharmacologic inhibition of CD73 [17] or anti-CD73 anti-
bodies [17], which all suggest a stimulating effect of host
CD73 on local tumor growth and metastatic spread. In
particular, tumor cells (colon adenocarcinoma, melanoma,
lymphoma) which additionally express immunogenic anti-
gens showed an impressive positive effect of host CD73
on tumor growth, especially when compared to their re-
spective less-immunogenic parent tumor cell lines [14,15].
Yet, not all studies showed a clear promoting role of
CD73 on tumor progression, especially when using less
immunogenic tumor cell lines [14,15]. It also should be
noted that systemic application of inhibitors or antibodies
targets CD73 on tumor cells as well as host immune cells
and vascular endothelium to the same extent. Finally, clin-
ical studies tested CD73 expression on tumor cells as a
prognostic marker has yielded contradictory results
[18,19]. In view of these findings, there is clearly a need to
further specify the role of host CD73 on local tumor
growth and metastatic spread.
The aim of the current study was to investigate the
role of host CD73 on tumor progression of B16-F10
melanoma cells, a well-established tumor model for mel-
anoma growth in C57BL/6 mice [20,21]. To address this
question, global and endothelium-specific CD73−/− mu-
tant mice together with bone marrow chimeras to select-
ively delete CD73 on hematopoietic cells were used. For
the precise assessment of tumor size and peritumoral
edema 1H magnetic resonance imaging (MRI) at 9.4 T
was used. Because the orthotopic site of spontaneous
malignant melanoma is the dermoepidermal junction
zone, we also injected tumor cells intradermally, therebyproviding a condition which may better mimic spontan-
eous tumor progression of melanoma. To investigate
hematogenous metastasis we also measured pulmonary
seeding after intravenous injection of melanoma cells.
Methods
Animals
All experiments were performed with approval of the
local government committee, the “Landesamt fuer Natur,
Umwelt und Verbraucherschutz Nordrhein-Westfalen”.
Generation of C57BL/6 J CD73−/− mice has been de-
scribed previously [22]. For generation of endothelium
specific CD73−/− (eCD73−/−) mice, Tie2-Cre+ mice [23]
were crossed with CD73flox/flox (loxP) mice (controls)
[22] to generate Tie2-Cre+ CD73flox/WT mice. Tie2-Cre+
CD73flox/WT mice were then crossed with CD73flox/flox
mice to generate Tie2-Cre+ CD73 flox/flox (eCD73−/−)
mice which specifically lack CD73 only on endothelial
cells. Targeted deletion of CD73 on endothelial cells of
eCD73−/− mice was confirmed by immunohistochemis-
try (Additional file 1: Figure S1).
Cell culture
Murine B16-F10 melanoma cells (ATCC, USA) were cul-
tured in DMEM/10% (v/v) fetal calf serum/2 mM L-glu-
tamine/100 U/ml penicillin/100 μg/ml streptomycin (all
Life Technologies, Germany) at 37°C and 5% (v/v) CO2.
Enzyme activity assays
B16-F10 cells (5 × 104) were incubated in RPMI-1640/
10% (v/v) fetal calf serum/2 mM L-glutamine for 24 h at
37°C and 5% (v/v) CO2. Thereafter, medium was chan-
ged and cells were incubated for another 20 min. To
inhibit AMPase activity 50 μM levamisole or 50 μM
AOPCP was used. The reaction was started with 50 μM
etheno-AMP. After 10 min, 20 min, 30 min, 40 min and
50 min 15 μl supernatant was removed, immediately
mixed with the same volume 1 M perchloric acid and
stored at −20°C until further analysis.
Samples were neutralized with 1 M K3PO4 prior
to HPLC analysis. Etheno-AMP and etheno-adenosine
amounts were determined using a 1525 Binary HPLC
pump (Waters, Germany) which was connected to
Waters 2475 multi wavelength fluorescence detector
(λEm = 410 nm, λEx = 280 nm). Separation of the two
analytes was achieved on an XTerra MSC18 Column
(Waters, 5 μm, 4.5 × 100 mm). Solution A contained 6%
(v/v) acetonitrile/5.7 mM tetrabutylammonium bisulfate/
30.5 mM KH2PO4, pH 5.8. Solution B consisted of 66%
(v/v) acetonitrile/5.7 mM tetrabutylammonium bisulfate/
30.5 mM KH2PO4, pH 5.8. At a flow rate of 0.75 ml/min
separation was achieved by a linear gradient from 0 to
34% (v/v) solution B for 5.6 min and 34% (v/v) solution B
for 1.4 min. Areas from the appropriate chromatograms
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given as enzymatic activity per 1 × 106 cells by using
Waters Breeze software. Each sample was measured in
triplicate.
Bone marrow transplantation
Bone marrow cells from WT and CD73−/− mice were
isolated from shinbone and calf bone of female donor
animals, washed in PBS and filtrated through a 70 μm
nylon mesh. 1 × 107 cells were intravenously injected
(tail vein) into male host animals, which were irradiated
(8 Gy) 24 h before. For infection prophylaxis 80 mg/l
vancomycin (Hexal, Germany) and 40 mg/l enrofloxacin
(Bayer, Germany) were given with drinking water start-
ing one week before irradiation and lasting five weeks
post bone marrow transplantation. Success of transplant-
ation was verified by FISH analysis using peripheral
blood after the individual experiments. All male animals
were 14 weeks old for tumor cell injection and had >
97% of female blood cells demonstrating the success of
the transplantation.
Tumor models
Appropriate numbers of B16-F10 cells were suspended
in PBS and checked for viability using trypan blue stain-
ing. Only when cell viability was > 90% the cell batch
was considered for injection. For subcutaneous or intra-
dermal application skin of mice at an age of 6–10 weeks
was shaved at the site of injection. Three different tumor
models were used: (1) for subcutaneous injection 25 ×
104 cells in 100 μl PBS were injected into the right hind
limb right beneath the hip, (2) for intradermal injections
1 × 106 cells in 100 μl PBS were injected into the right
flank, (3) for intravenous injection 25 × 104 cells in
250 μl PBS were injected into the tail vein of the ani-
mals. In the first two models growth of the tumor was
assessed over time by MRI. At the end of the experi-
ments, tumors were isolated and used for the analysis of
immune cell subpopulations by FACS.
Tumor volume determination using MRI
For determination of tumor volume and tumor edema
volume 1H MRI was performed and images were plani-
metrically analyzed. Mice were anesthetized with 1.5%
(v/v) isoflurane in a water-saturated gas mixture of 30%
(v/v) oxygen in nitrogen applied at a rate of 75 ml/min
by manually restraining the animal and placing its head
in an in-house-built nose cone. Measurements were
performed in a vertical Bruker DRX 9.4 T wide-bore
NMR spectrometer which was equipped with a 40 mm
gradient system and a linear 30 mm saw-resonator. For
2D-multislice-RARE sequences (identical to the turbo-
spin-echo-sequence) the following parameters were used:
repetition time (TR) = 3.5 s, echo time (TE) = 15.8 ms,field of view (FOV) = 3 × 3 cm2, matrix size = 256 × 192
(zero filling to 256 × 256 resulted in a pixel size of 117 ×
117 μm2), acquisition time = 2.8 min. The tumor was
scanned in 30 consecutive axial 1-mm slices. For evalu-
ation of volumes areas of solid tumor and edema tissue
were determined in each slice and volume was calculated
taking the slice thickness of 1 mm into account.
Tumor cell separation, FACS analysis and IFN-γ-ELISpot
After cervical dislocation of mice, tumors were excised,
minced and then incubated in an enzyme mixture
(7.5 mg collagenase type I, 2.5 mg hyaluronidase type I-S
(both Sigma-Aldrich, Germany) in 10 ml PBS) at 37°C
for 1 h. After filtration of the cell suspension through a
100 μm nylon mesh erythrocytes were lyzed in 155 mM
NH4Cl, 10 mM KHCO3, 0.1 mM Na2-EDTA (pH 7.4,
4°C, 8 min) and washed with PBS.
For FACS analysis cells were stained using the fol-
lowing anti-mouse antibodies: anti-CD4-FITC, CD8a-
FITC, CD11b-FITC, CD11c-FITC, CD45-APC (all BD,
Germany), CD25-PE (Miltenyi Biotec, Germany), as
well as appropriate isotype controls. Cells were fixed in
4% (v/v) paraformaldehyde after staining. Analysis was
performed on a BD FACSCanto II using the FACS Diva
Software (both BD, Germany). Gates of immune cell
subpopulations were defined by staining with respect-
ive isotype control antibodies and fractions are given
as percentage of CD45+ immune cells.
For the IFN-γ-ELISpot 2 × 105 cells of the tumor were
used and protocol was run according to the manufac-
turer’s specification (R&D Systems, Germany). The num-
ber of IFN-γ secreting cells was determined by counting
the number of visible spots on the plate.
Statistics
All results are presented as mean values ± standard error
of the mean (SEM). Results were analyzed by two-tailed
Student’s t-test. Differences were considered to be statis-
tically significant at a value of p < 0.05.
Results
B16-F10 cells have low intrinsic AMPase activity
For analysis of intrinsic ecto-AMPase activity in B16-F10
tumor cells, enzymatic conversion of etheno-AMP to
etheno-adenosine was measured by HPLC. As shown in
Figure 1, AMPase activity (8.4 ± 2.1 nmol × h−1× 10−6
cells) on B16-F10 cells was rather small, particularly
when comparing it with the extracellular ATP concentra-
tions reported to be within the hundreds of micromolar
range in solid tumors [24]. CD73 activity was measured by
blocking alkaline phosphatase (AP) with levamisole and
AP activity was determined by using the specific CD73 in-
hibitor AOPCP. B16-F10 cells catalyzed dephosphoryla-































Figure 1 Low ecto-AMPase activity in B16-F10 cells. AMPase
activity was measured by the dephosphorylation of etheno-AMP to
etheno-adenosine in cultured B16-F10 cells using HPLC. CD73 and
alkaline phosphatase (AP) activity were assessed using the AP
inhibitor levamisole (50 μM) and the CD73 inhibitor AOPCP (50 μM)


























Figure 2 Global loss of host CD73 did not alter subcutaneous B16-F10
into the hindlimb of WT and CD73−/− mice. (A, B) Representative MRI mea
18 days post injection. Tumor volume and peritumoral edema are encircled
or peritumoral edema volume were observed (n = 10).
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a rather low CD73 activity is in accordance with results
from others who failed to detect any CD73 expression on
B16-F10 cells by less sensitive techniques [14,16].Role of host CD73 on tumor growth after subcutaneous
injection of B16-F10 cells
Because B16-F10 cells exhibit only minimal CD73 activ-
ity, this enabled us to study the role of host CD73 on
tumor growth. To this end B16-F10 cells were injected
subcutaneously into the hindlimb of WT and CD73−/−
mice at a concentration (25 × 104 cells) previously used
by others [9,14,17,25]. Tumor growth and peritumoral
edema formation was monitored by MRI at 9.4 T for
18 days, as shown in representative images in Figure 2A-B.
From the quantitative data summarized in Figure 2C-D it is
obvious that there were no differences between WT and
global CD73−/−mice when either tumor volume (Figure 2C)
or peritumoral edema formation around the solid tumor































tumor growth. B16-F10 cells (25 × 104) were injected subcutaneously
surements of the tumor and peritumoral edema were performed for






























Figure 3 Loss of host CD73 did not alter intratumoral immune response of B16-F10 tumors. Subcutaneously injected B16-F10 tumors,
reported on in Figure 2, were excised on day 18 post injection, minced and enzymatically separated into single cell suspension. Immune cell
subsets were measured with FACS. Representative dot plots of CD4+ T helper (A), CD8+ cytotoxic T cells (B), CD4+ CD25+ T cells (C), CD11b+
(D) and CD11c+ myeloid cells (E) are shown (gated cells are marked in red). (F) No differences in immune cell composition of tumors from WT


























































Figure 4 Loss of CD73 on vascular endothelial cells did not affect B16-F10 tumor growth. (A, B) B16-F10 cells (25 × 104) were injected
subcutaneously into the hindlimb of loxP and endothelium specific CD73−/− (eCD73−/−) mice and MRI measurement of tumor and peritumoral
edema were performed for 18 days post injection (n = 7). Compared with WT mice (n = 10) loxP and eCD73−/− mice showed a significantly
increased tumor growth (p = 0.04 for loxP and p = 0.03 for eCD73−/− mice respectively on day 18) and a trend towards an increased peritumoral
edema formation (p = 0.07 and p = 0.08 respectively on day 18). Data are shown as mean ± SEM. *p < 0.05.
Burghoff et al. BMC Cancer 2014, 14:898 Page 5 of 11
http://www.biomedcentral.com/1471-2407/14/898
Burghoff et al. BMC Cancer 2014, 14:898 Page 6 of 11
http://www.biomedcentral.com/1471-2407/14/898At the end of the experiments, B16-F10 tumors were
excised and immune cell distribution within the tumor
was measured by FACS (Figure 3A-E). As shown in
Figure 3F, we found no differences between the two ex-
perimental groups regarding the distribution of lymphoid
and myeloid immune cell subsets, thus suggesting no
changes of immune response in absence of host CD73.
Similar experiments as with the global CD73 knockout
were carried out in mice in which CD73 on vascular endo-
thelium was selectively deleted (Tie2-Cre+ CD73 flox/flox
mice). As shown in Figure 4A-B, there were no differences
in tumor growth and peritumoral edema formation be-
tween the loxP control and the endothelium specific
knockout mice. Note, however, that tumor growth and
edema formation in both experimental groups were higher
at day 18 when compared with respective values in WT
controls (Figure 4A-B), suggesting an influence of the gen-
etic background.
That the genetic background can influence the growth
of B16-F10 cells became also obvious when we used
chimeric mice in which bone marrow from CD73−/−
mice was transplanted to WT mice, resulting in the loss of
CD73 on hematopoietic cells. As appropriate controls, WT
mice were treated accordingly and received autologous
bone marrow from the WT genotype. In all cases, bone
marrow from female mice was transplanted into male mice
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Figure 5 Loss of CD73 on hematopoietic cells did not affect B16-F10
was grafted to WT mice after whole-body irradiation. B16-F10 cells (25 × 10
grafted mice. (A, B) MRI measurement of tumor and peritumoral edema w
cell composition within tumor were observed in FACS. Data are shown asby FISH. Using the identical protocol of B16-F10 cell inocu-
lation as above, we again found no significant differences
between the two experimental groups after 17 days in
tumor volume, edema formation and infiltrating immune
cells (Figure 5A-C). However, tumor growth and edema
formation in WT mice transplanted with WT bone marrow
was significantly reduced when compared with the controls
in respective experiments in global (Figure 2C-D) and
endothelium specific CD73 mutants (Figure 4A-B).
Intradermal injection of B16-F10 cells influences tumor
edema but not tumor growth
Using a potentially more immunogenic approach, we
next inoculated B16-F10 cells intradermally into the
flank of mice (Figure 6A-B) as previously described [26].
Although absence of host CD73 did not affect tumor
growth (Figure 6C), peritumoral edema was found to be
significantly attenuated in CD73−/− mice (Figure 6D).
Similar to the subcutaneous approach, we observed no
differences in tumor immune cell response between WT
and CD73−/− mice (Figure 6E).
We next investigated whether the observed effect on
tumor edema was caused by the loss of CD73 on
hematopoietic cells. Therefore bone marrow transplanted
chimeric mice (see above) were challenged with intrader-
mally applied B16-F10 tumor cells. As expected, tumor
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tumor growth and immune response. WT or CD73−/− bone marrow
4) were injected subcutaneously into the hindlimb of bone barrow
as performed on day 17 post injection. (C) No differences in immune


















































































Figure 6 B16-F10 peritumoral edema but not tumor volume was reduced in CD73−/− mice after intradermal injection. B16-F10 cells
(1 × 106) were injected intradermally into the flank of WT and CD73−/− mice. MRI measurement of tumor and peritumoral edema was
performed for 10 days post injection. Representative MR images of one WT (A) and one CD73−/− (B) mouse bearing tumor (arrow) are shown.
(C, D) Tumor volume was not altered by lack of CD73 in mice, while peritumoral edema was significantly decreased in CD73−/− mice
(n = 8 – 10). (E) No differences were observed in immune cell subsets analyzed in tumors from WT and CD73−/− mice (n = 4 – 6). Data are
shown as mean ± SEM. *p < 0.05.
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mice reconstituted with CD73−/− bone marrow (Figure 7B).
Thus, CD73 on non-hematopoietic cells, most likely endo-
thelial cells, mediated the observed effect on peritumoral
edema (Figure 6D). Differences in intratumoral immune
response cannot explain this observation, since FACS ana-
lysis and IFN-γ-ELISpot of tumors from both experimen-
tal groups showed no differences (Figure 7C-D).
Loss of host CD73 did not affect lung metastasis of
B16-F10 cells
Finally we investigated the role of CD73 on hematogenic
metastasis by injecting 25 × 104 B16-F10 cells intravenouslyinto mice and harvesting the lungs after 10 days. As shown
in the representative Figure 8A-B and the statistical
evaluation in Figure 8C, no difference was observed in the
number of metastatic nodules on the lung surface between
WTand CD73−/− mice.
Discussion
Experimental evidence summarized in several recent re-
views [4,27,28] suggests that inhibition of CD73, which
catalyzes the extracellular production of adenosine from
AMP, has the potential to reduce tumorigenesis and me-
tastasis by enhancing antitumor T cell immunity via ad-



















































































































Figure 7 Loss of CD73 on hematopoietic cells did not reduce peritumoral edema after intradermal B16-F10 application. WT mice
received bone marrow graft from WT or CD73−/− mice after whole-body irradiation. B16-F10 cells (1 × 106) were injected intradermally into the
flank of bone barrow grafted mice. MRI measurement of tumor and peritumoral edema was performed over 14 days post injection. (A, B) Tumor
and peritumoral edema volume, respectively (n = 8). (C) Loss of CD73 on hematopoietic cells did not alter intratumoral lymphoid and myeloid
immune cell subsets (n = 4). (D) IFN-γ-ELISpot was performed in single cell suspensions of digested tumors containing both tumor and infiltrating
immune cells. No difference was observed in the number of IFN-γ secreting cells in both groups (n = 4). Data are shown as mean ± SEM.
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in mutants lacking CD73 [13-16] or inhibitors of CD73
[17] or systemically applying anti-CD73 antibodies [17].
On the other hand, B16-F10 cells which were altered to
overexpress CD73 showed no differences in local tumor
growth [10]. The present study reports, that specific loss
of host CD73 in different transgenic mouse models has
no significant influence on tumorigenesis when B16-F10
melanoma cells were injected either subcutaneously or
intradermally or intravenously.
Similarly to data in the literature [14,16,17] we injected
25 × 104 B16-F10 melanoma cells subcutaneously but
found no differences in tumor growth and immune cell
subset composition within the tumor when using a glo-
bal CD73 knockout, an endothelium specific CD73
knockout or a CD73 knockout on hematopoietic cells
generated by bone marrow transplantation. In particular,
no differences were observed in the important cell
fractions involved in antitumoral immune response: CD4+
T helper, CD8+ cytotoxic T and CD4+ CD25+ T cells.
Whether there were changes in distinct polarized macro-
phage subsets has not been investigated by us. Overall our
data suggest that neither the CD73 on invading immune
cells nor the CD73 on tumor vessels influenced local
growth of the melanoma cells. Consistent with this findingwe found that intradermal injection of B16-F10 melanoma
cells did not alter tumor growth in the CD73 mutant.
The reasons for our surprising findings are not imme-
diately obvious. In the present study we took great care
to standardize the experimental procedures by using
only freshly thawed B16-F10 cells (obtained from ATCC)
of the same passage, which were regularly checked for
viability and mycoplasma. In the different experimental
series, melanoma cells were kept at 4°C and were
injected within 2 hours after cell collection to minimize
changes in cell quality. We also purposely alternated the
injection between WT and knockout mice on a one by
one basis to achieve a homogenous distribution between
the experimental groups. Finally we have measured
tumor expansion in a sufficient number of animals (n =
10) with MRI which permitted the precise volume deter-
mination over time when compared with caliper meas-
urement in literature [13-17]. Whether differences in
cell handling and experimental protocol may explain
some of the differences reported in the literature [13-17]
cannot be decided on the basis of published data.
Aside from differences in the experimental protocol
additional factors may have also played a role. It is well
known that the genetic background can influence tumor


















Figure 8 Loss of host CD73 did not alter lung metastasis. 25 × 104 B16-F10 cells were injected into the tail vein of WT and CD73−/− mice.
Lungs of mice were removed after 10 days and the number of visible black metastatic nodules on the lung surface was counted. Representative
images of lungs from one WT (A) and one CD73−/− (B) mouse is shown. (C) No differences in the metastatic load of lungs were observed
between WT und CD73−/− mice. Data are shown as mean ± SEM (n = 8).
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tion strategies [22,31], so that positional effects might have
influenced the outcome. In the present study we have ob-
served that in experiments using the endothelium specific
CD73 mutant, the corresponding loxP controls showed a
stronger tumor growth and edema formation when com-
pared to WT controls of the global CD73 knockout. Like
other groups [14,15], we have observed similar effects in
chimeric mice in which WT mice with WT bone marrow
transplantation showed an attenuated growth of tumor
size and edema versus WT mice without transplantation.
That genetic background and positional effects may influ-
ence the phenotype is well known in the literature [32].
Differences in intestinal commensal microbes, known
to be important immune modulators [33] must also be
considered. It is becoming increasingly apparent that
differences in the gut microbiome can significantly influ-
ence the disease expression in rodents [34] and also
humans [35]. Routine microbiological monitoring ac-
cording to FELASA recommendations [36] of the ani-
mals used in the present study did not reveal any
evidence for common murine pathogens except for Pas-
teurellaceae and Protozoa. No information is available,
however, on the health status of mice from two of the
published melanoma studies [16,17] while Koszalka et al.reported to have used specific pathogen free (SPF) ani-
mals [13].
It has been suggested that adenosine may regulate the
vascular supply to neoplastic tissue thereby influencing
the growth of tumors [37]. More recently we have
shown that CD73 in addition influences arteriogenesis
[38]. Moreover, CD73 may enhance vascular permeabil-
ity by induction of adhesion proteins on endothelial cells
[39] and the extracellular fluid of solid carcinomas was
shown to contain biologically active concentrations of
adenosine [40]. Our results are consistent with a role of
adenosine in vascular permeability of vessels supplying
the tumor in which after intradermal cell application the
peritumoral edema was significantly reduced in CD73
mutants. This difference was fully abrogated in chimeric
mice with CD73−/− bone marrow suggesting that the
CD73 on non-hematopoietic cells (likely endothelial
cells) accounts for the reduced peritumoral edema in the
global CD73 knockout.
Tumor cells greatly differ in their expression of CD73
and its role on disease progression is somewhat contro-
versial [5,28]. In a study on human breast cancer cells a
positive correlation between CD73 and metastasis was re-
ported [18] while in contrast a later study in breast carcin-
oma found CD73 to be a marker of good prognosis [19].
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which were injected intravenously in the murine model
showed enhanced metastasis into the lung while similar to
our results, local growth was not affected after subcutane-
ous inoculation [10]. This is in accordance with reports of
an association of tumor CD73 with other metastasis pro-
moting antigens and preference for hematogenic metasta-
sis in melanoma [41,42]. On the other hand, loss of host
CD73 did not affect lung metastasis in our experiments in
contrast to another report [14].
The B16-F10 melanoma cells used in the present study
showed a rather low CD73 activity which matches FACS
data from other groups which failed to detect CD73 on
the surface of B16-F10 cells [14,16]. Thus, CD73 on
B16-F10 cells can be expected to produce adenosine
only at a negligible rate. It is therefore conceivable that
the low CD73 expression prevented the generation of an
adenosine-mediated immunosuppressive environment
involving the activation, clonal expansion and homing of
tumor-specific CD4+ T helper and CD8+ cytotoxic T
cells. In this context it is also unknown whether B16-
F10 melanoma cells in vivo release similar high quan-
tities of ATP as it was elegantly shown for OVCAR-3
human ovarian carcinoma and MZ2-MEL human mel-
anoma cell lines [24].
The adenosine concentration in the tumor microenvir-
onment depends on the ATP release from tumor cells
themselves [2] but also from the invading immune cells
[3]. Furthermore, it is the activity of the ATP degrading
enzymes CD39 and CD73 which dictates half-life of ATP
and rate of adenosine formation. The situation is further
complicated by the fact that not only adenosine influ-
ences tumor growth but also extracellular ATP acting on
P2 receptors [43,44]. Furthermore, adenosine has been
reported to inhibit tumor growth via A3 receptor both
directly on melanoma cells [25] and indirectly by activat-
ing NK and CD8+ cells [9]. It should also be noted, that
CD73, aside of its enzymatic activity in producing adeno-
sine, has been reported to bind to the extracellular matrix
protein tenascin C which promotes tumor cell migration
in a non-enzymatic fashion [11]. Interestingly, binding of
CD73 to tenascin C strongly inhibits enzymatic activity of
CD73, so that the migration stimulating effect of tenascin
C may not be dependent on adenosine [11].
Conclusions
The present study demonstrates that lack of CD73 on
immune and endothelial cells did not cause robust in-
hibition of tumor growth and metastasis when B16-F10
melanoma cells were applied by different modes. B16-
F10 cells showed negligible CD73 activity which limited
its contribution to an adenosinergic tumor microenvir-
onment. Under this condition lack of CD73 on host cells
alone failed to generate a proinflammatory state whichwould be of sufficient magnitude to inhibit local tumor
growth and metastatic spread. Whether overexpression
of ecto-nucleotidases (CD39, CD73) on tumor cells plays
a more profound role in adenosine-triggered tumor im-
mune escape cannot not be decided on the results ob-
tained in this study. It is also possible that the relative
contribution of tumor versus host CD73 may be differ-
ent for different tumors.
Additional file
Additional file 1: Figure S1. Immunohistochemistry of carotid artery in
Tie2-Cre+ CD73 flox/flox (eCD73−/−) mice. Immunohistochemical analysis of
carotid artery showed strong CD73 expression (red) on endothelial cells
of CD73flox/flox (loxP) mice (A) und lack of CD73 activity on endothelium
in eCD73−/− mice (B). Smooth muscle cells were identified by staining
with α-SMA (green) and nucleus with DAPI staining (blue). Bars: 200 μm.
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